ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO879

A 10-Year Analysis of IgAN Management in China: Results from the CPO-IGAN Study

Session Information

Category: Glomerular Diseases

  • 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics

Authors

  • Lin, Fujun Fiona, Renal Division, Department of Internal Medicine, Xin Hua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
  • Jiang, Gengru, Renal Division, Department of Internal Medicine, Xin Hua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
  • Wang, Rong, Shandong Provincial Hospital, Jinan, Shandong, China
  • Chen, Chaosheng, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
  • Chen, Qinkai, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
  • Li, Wenge, China-Japan Friendship Hospital, Beijing, Beijing, China
  • Xing, Chang Ying, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
  • Wang, Niansong, Shanghai 6th Peoples Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, China
  • Jiang, Hongli, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China
  • Yang, Zhenhua, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
  • Wu, Yonggui, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
  • Fu, Ping, West China Hospital of Sichuan University, Chengdu, Sichuan, China
  • Liu, Hong, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
  • Fan, Qiuling, First People's Hospital Affiliated to Shanghai Jiaotong University, Shanghai, China
  • Xue, Hen, Ya'an People's Hospital, Ya'an, Sichuan, China
  • Bi, Guangyu, Northern Jiangsu People′s Hospital, Yangzhou, Jiang Su, China
  • Zhang, Qinghong, Taihe Hospital, Shiyan, Hubei, China
  • Li, Xinjian, Affiliated Hospital of Jining Medical University, Jining, Shandong, China
  • He, Siyi, Tianjin Happy Life Technology Co. Ltd, Shanghai, China
  • Zhu, Bingbing, Tianjin Happy Life Technology Co. Ltd, Shanghai, China
Background

Nationwide data on the treatment of IgA nephropathy (IgAN) in Chinese patients remains unclear.Clinical Practice Optimization Initiative for Chinese Patients with IgA Nephropathy (CPO-IGAN),the first nationwide project to optimize IgAN clinical practices in China,conducted a 10-year nationwide analysis to assess adherence to evidence-based guidelines.

Methods

This retrospective study recruited biopsy-proven IgAN patients across China from January 2015,age ≥18 years with at least one follow-up after treatment initiation.Demographic factors,comorbidities,laboratory results,renal histology reports and therapeutic regimens were collected from clinical information systems.

Results

By April 2024, 2229 IgAN patients from 33 tertiary hospitals in 12 Chinese provinces had been recruited.Table 1 summarizes the clinical characteristics at the time of renal biopsy.74.3% and 5.4% of patients received RASi and SGLT2i as supportive treatment respectively.As shown in Table 2, SGLT2i use increased after the 2021 publication of the DAPA-CKD IgAN subgroup results.46.0% and 6.2% of patients recevied corticosteroids and MMF,and Figure 1 shows the characteristics of these patients.MMF use increased following the KDIGO 2021 guideline recommending it for Chinese IgAN patients.

Conclusion

Optimized treatment of IgAN in China,including the addition of SGLT2i as the new standard of care needs to be implemented. Accordingly,CPO-IGAN will conduct nationwide training to raise awareness among Chinese nephrologists.Given the high use of corticosteroids and MMF in Chinese IgAN patients,disease progression and long-term prognosis will be analyzed through further longitudinal studies by CPO-IGAN.